SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 19, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $299K total
Actionable Insight • Neutral

The insider selling is immaterial relative to market cap and likely liquidity-driven. Monitor for any upcoming earnings or pipeline catalysts (e.g., FDA decisions on ZORYVE) that could drive the stock, but this cluster provides no actionable signal.

DirectionNeutral
Confidencehigh
Horizondays

ZORYVE

▲ Bullish Named in this insider cluster
Impact
Phase
Approved (commercial stage)
Time to market
Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
Next catalyst
PDUFA date · Feb 23, 2027 99d

What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.35
T+0 close · Aug 19, 2026 · via day close
Latest settled
+11.48%
T+60 · $28.26
Vs SPY
+12.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $25.35entry
  2. T+1 · 3mo ago −1.07%α −1.47% · $25.08
  3. T+5 · 3mo ago −1.89%α −3.01% · $24.87
  4. T+20 · 2mo ago +0.12%α +0.12% · $25.38
  5. T+60 · 4d ago +11.48%α +12.56% · $28.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Arcutis Biotherapeutics sold a combined $299K in open-market sales over a week, with Director Welgus Howard G. also exercising multiple derivative options for cash and non-cash transactions. The total sales represent approximately 0.009% of the company's $3.3B market cap, making the cluster trivial in size and unlikely to reflect material negative information. The sales are likely routine liquidity events, especially given the concurrent option exercises and the company's strong analyst consensus (86% bullish).

Key Financial Metrics

Direction
selling
Total Value
$299.0K
Insiders
2

Key Facts

  • Two insiders sold a total of $299K in open-market sales (0.009% of $3.3B market cap)
  • Director Welgus Howard G. exercised multiple derivative options (cash and non-cash) on the same day as his sale
  • Patrick Burnett sold 6.7K shares for $175K on 2026-08-12
  • Welgus Howard G. sold 4.7K shares for $124K on 2026-08-17
  • Total insider activity in the last 30 days is $299K in sells, with no buys
  • Analyst consensus is 86% bullish (12 Buy, 2 Hold, 0 Sell)

Financial Impact

Insider sales of $299K represent 0.009% of market cap, trivial and routine

insider_sales

Risk Factors

  • Insider sales, while small, could be followed by larger sales if insiders have more information
  • No insider buying to offset the selling signal
  • Biotech sector risk: any negative pipeline news could amplify concerns

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ARQT-1787173284966

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026